| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df7cc20da5ebeba781e2ec396a347ff8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
| filingDate |
2022-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8104a51d408b1b014d6aaf310f4f2059 |
| publicationDate |
2022-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022240754-A2 |
| titleOfInvention |
Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody |
| abstract |
The present disclosure provides a model to mathematically explore and predict the pharmacokinetic and pharmacodynamic relationships between of PB2452, its interaction with ticagrelor and the active metabolite, and the ability of PB2452 to reverse the antiplatelet effects of ticagrelor. This model may be used to determine dosing regiments of PB2452 for a particular patient population. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11773186-B2 |
| priorityDate |
2021-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |